NICE Endorses AstraZeneca’s Tagrisso for NSCLC Patients With Specific Mutation
The UK’s National Institute for Health and Care Excellence (NICE) has said the Cancer Drugs Fund, part of the National Health Service, should offer AstraZeneca’s Tagrisso (osimertinib) for patients with non-small cell lung cancer (NSCLC).
NICE recommended the drug for people with early-stage NSCLC who have had prior surgery to remove a tumor and who suffer from epidermal growth factor receptor (EGFR) genetic mutations.
Tagrisso blocks the mutated EGFR protein which causes cancer growth and may also help shrink tumor size.
December 6, 2021